Certuity’s Corcept Therapeutics CORT Stock Holding History

Certuity’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Sell	2,453 -88	-3%	-$5.31K	0.01%	608
2026 Q1	$102K	Sell	2,541 -4,692	-65%	-$175K	0.01%	631
2025 Q4	$252K	Hold	7,233	–	–	0.02%	479
2025 Q3	$601K	Buy	+7,233	New	+$523K	0.04%	227
2025 Q2	–	Sell	-2,581	Closed	-$295K	–	433
2025 Q1	$295K	Sell	2,581 -1,472	-36%	-$89.6K	0.03%	271
2024 Q4	$204K	Buy	+4,053	New	+$212K	0.02%	349
2022 Q2	–	Sell	-9,343	Closed	-$210K	–	237
2022 Q1	$210K	Buy	+9,343	New	+$199K	0.05%	278
2021 Q3	–	Sell	-9,293	Closed	-$204K	–	405
2021 Q2	$204K	Buy	+9,293	New	+$207K	0.05%	315
2021 Q1	–	Sell	-7,915	Closed	-$207K	–	317
2020 Q4	$207K	Buy	+7,915	New	+$167K	0.07%	215

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Certuity's CORT Position: Q2 2026 in Review

Certuity reduced its Corcept Therapeutics (CORT) stake by 3.5% in Q2 2026, selling an estimated $5.31K and leaving 2,453 shares worth $213K. The position accounts for 0.01% of the portfolio, ranked #608.

Certuity first reported a position in CORT in Q4 2020 and has held it in 9 quarters since. The position peaked at $601K in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Certuity held 2,453 shares of Corcept Therapeutics worth $213K as of Q2 2026.
Certuity sold 88 Corcept Therapeutics shares in Q2 2026, an estimated $5.31K.
Corcept Therapeutics made up 0.01% of Certuity's portfolio in Q2 2026, its #608 holding.
Certuity first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 9 quarters since.
Certuity's Corcept Therapeutics position peaked at $601K in Q3 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Certuity's 13F filing for Q2 2026, filed 28 Jul 2026.